Preparation of magnetite-chitosan/methylcellulose nanospheres by entrapment and adsorption techniques for targeting the anti-cancer drug 5-fluorouracil
Source abstract
Abstract
In this work, we have formulated novel nanospheres that could be used in the controlled release of the anticancer drug, 5-fluorouracil (5-FU). The nanospheres are composed of magnetite, containing chitosan (CS) and methylcellulose (MC). The drug entrapment was achieved through the encapsulation and adsorption processes. The effects of the preparation conditions, such as magnetite content, CS/MC ratio, crosslinking concentration, exposure time to glutaraldehyde (GA), and the drug/polymer ratio were investigated for both processes. The 5-FU release was found to follow the Fickian mechanism, and the Langmuir isotherm for the nanospheres was achieved through encapsulation and adsorption processes, respectively.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanomaterials for catalytic reactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. 10.1002/app.2276010.1002/app.22760 ↗
2. 10.1002/nbm.92410.1002/nbm.924 ↗
3. 10.1016/j.biomaterials.2008.12.01710.1016/j.biomaterials.2008.12.017 ↗
4. 10.1016/j.reactfunctpolym.2004.02.01810.1016/j.reactfunctpolym.2004.02.018 ↗
5. 10.1016/j.mehy.2009.01.03110.1016/j.mehy.2009.01.031 ↗
6. Dorniani D · Int J Nanomed · 2012 · 7 · 574510.2147/IJN.S35746 ↗
7. Gan ZF · J Biomed Mater Res · 2008 · 84 · 1010.1002/jbm.a.31181 ↗
8. Gu HW · Chem Commun · 2006 · 12 · 94110.1039/b514130c ↗
9. Guo SJ · Biomaterials · 2009 · 30 · 188110.1016/j.biomaterials.2008.12.042 ↗
10. 10.1016/j.biomaterials.2004.10.01210.1016/j.biomaterials.2004.10.012 ↗
11. 10.1016/j.carbpol.2009.11.00710.1016/j.carbpol.2009.11.007 ↗
12. 10.1002/app.2201210.1002/app.22012 ↗
13. 10.1002/app.2857710.1002/app.28577 ↗
14. İnal M · e-Polymers · 2008 · 8 · 17710.1515/epoly.2008.8.1.177 ↗
15. Jing XH · Jt Bone Spine · 2008 · 75 · 43210.1016/j.jbspin.2007.09.013 ↗
16. 10.1016/S0031-6865(99)00015-110.1016/S0031-6865(99)00015-1 ↗
17. 10.1002/app.1155210.1002/app.11552 ↗
18. 10.1002/app.1238610.1002/app.12386 ↗
19. Kuroiwa T · Process Biochem · 2008 · 43 · 6210.1016/j.procbio.2007.10.014 ↗
20. 10.1021/jm800767c10.1021/jm800767c ↗
21. 10.1016/j.jallcom.2007.11.10010.1016/j.jallcom.2007.11.100 ↗
22. Loh JW · Toxicol Appl Pharm · 2010 · 249 · 14810.1016/j.taap.2010.08.029 ↗
23. Loh JW · Toxicol Appl Pharmacol · 2012 · 262 · 27310.1016/j.taap.2012.04.037 ↗
24. Lu A · Angew Chem Int Ed Engl · 2007 · 46 · 122210.1002/anie.200602866 ↗
25. Mao C · Colloid Surface B · 2004 · 38 · 4710.1016/j.colsurfb.2004.08.007 ↗
26. 10.1016/j.ijpharm.2009.01.00810.1016/j.ijpharm.2009.01.008 ↗
27. Mody VV · Appl Nanosci · 2014 · 4 · 38510.1007/s13204-013-0216-y ↗
28. Okon E · Lab Invest · 1974 · 71 · 895
29. Olukman M · J Biomater Nanobiotech · 2012 · 3 · 46910.4236/jbnb.2012.34048 ↗
30. Peppas NA · Pharm Acta Helv · 1985 · 60 · 110
31. 10.1016/j.bmcl.2005.01.01010.1016/j.bmcl.2005.01.010 ↗
32. 10.1016/0168-3659(87)90035-610.1016/0168-3659(87)90035-6 ↗
33. 10.1016/j.carbpol.2007.02.00810.1016/j.carbpol.2007.02.008 ↗
34. Saikia C · Artif Cell Nanomed B · 2014 · 4 · 1
35. 10.1016/S0939-6411(01)00205-310.1016/S0939-6411(01)00205-3 ↗
36. 10.1002/app.2959210.1002/app.29592 ↗
37. 10.1016/j.ijpharm.2009.03.04110.1016/j.ijpharm.2009.03.041 ↗
38. Xu Y · Biomed Res Int · 2013 · 2013 · 462589
39. 10.1016/j.ijpharm.2006.06.02910.1016/j.ijpharm.2006.06.029 ↗
40. Yao Q · J Nanomat · 2013
41. 10.1016/j.carbpol.2008.12.03410.1016/j.carbpol.2008.12.034 ↗
42. Zinutti C · Int J Pharm · 1996 · 133 · 9710.1016/0378-5173(95)04423-X ↗